Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.
2.

Central nervous system effects of haloperidol on THC in healthy male volunteers.

Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1697-708. doi: 10.1177/0269881109358200. Epub 2010 Feb 8.

PMID:
20142302
3.

Central effects of the diuretic, bendrofluazide.

McDevitt DG, Currie D, Nicholson AN, Wright NA, Zetlein MB.

Br J Clin Pharmacol. 1994 Sep;38(3):249-56.

4.

Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.

Liem-Moolenaar M, Gray FA, de Visser SJ, Franson KL, Schoemaker RC, Schmitt JA, Cohen AF, van Gerven JM.

J Psychopharmacol. 2010 Jan;24(1):73-82. doi: 10.1177/0269881108094524. Epub 2008 Aug 28.

PMID:
18755817
5.

Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers.

Ferrara SD, Giorgetti R, Zancaner S, Orlando R, Tagliabracci A, Cavarzeran F, Palatini P.

Eur J Clin Pharmacol. 1999 Jan;54(11):821-7.

PMID:
10027654
6.

The effects of sulpiride on psychomotor performance and subjective tolerance.

Meyer-Lindenberg A, Rammsayer T, Ulferts J, Gallhofer B.

Eur Neuropsychopharmacol. 1997 Aug;7(3):219-23.

PMID:
9213082
8.

Remoxipride versus haloperidol in healthy volunteers: psychometric performance and subjective tolerance profiles.

Rammsayer T, Gallhofer B.

Int Clin Psychopharmacol. 1995 Mar;10(1):31-7.

PMID:
7622802
9.

Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic.

Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, de Bie A, Rosenzweig P, Patat A, O'Hanlon JF.

J Clin Psychopharmacol. 1999 Jun;19(3):209-21.

PMID:
10350027
10.

Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood.

Currie D, Lewis RV, McDevitt DG, Nicholson AN, Wright NA.

Br J Clin Pharmacol. 1988 Aug;26(2):121-8.

11.
12.

Central effects of the calcium antagonist, nifedipine.

McDevitt DG, Currie D, Nicholson AN, Wright NA, Zetlein MB.

Br J Clin Pharmacol. 1991 Nov;32(5):541-9.

13.

Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood.

Currie D, Lewis RV, McDevitt DG, Nicholson AN, Wright NA.

Br J Clin Pharmacol. 1990 Oct;30(4):527-36.

14.
15.

Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety.

Mizuki Y, Suetsugi M, Ushijima I, Yamada M.

Prog Neuropsychopharmacol Biol Psychiatry. 1997 May;21(4):573-90.

PMID:
9194141
18.

Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies--Part I.

Saletu B, Grünberger J, Linzmayer L, Dubini A.

Int J Clin Pharmacol Ther Toxicol. 1983 Oct;21(10):489-95.

PMID:
6139346
19.

Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers.

Hughes AM, Lynch P, Rhodes J, Ervine CM, Yates RA.

Br J Clin Pharmacol. 1999 Sep;48(3):323-30.

20.

Effects of tiapride on electroencephalograms and cognitive functions in the elderly.

Patat A, Alberini H, Bonhomme D, Soubrane C, Allain H, Gandon JM.

Int Clin Psychopharmacol. 1999 Jul;14(4):199-208.

PMID:
10468312

Supplemental Content

Support Center